Work

386 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) phase I study of an oral c-Met inhibitor ARQ197 reaches maximum tolerated dose (MTD) in a twice daily (bid) dosing schedule

Year: 2008

Type: conference-abstract

Source: European Journal of Cancer Supplements

DOI: 10.1016/s1359-6349(08)72320-6

Authors: T.A. Yap, J. Barriuso, S. Frentzas, R. Riisnaes, J. Clark, J. Dukes, A. Futreal, R.E. Savage, F. Chai, J.S. de Bono

Language: English

Topic: Antibiotics Pharmacokinetics and Efficacy

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2045747572

Cites:

Cited by: 2

Related to: 10